Project Grant F30CA298502
- This Project Grant award of $489,767.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to develop T-cell products for the treatment of Neurofibromatosis Type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). The research aims to identify relevant tumor antigens and target the epigenome to enhance T-cell-mediated therapies for this rare and...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $699,559 to Merlin Therapeutics Inc. to develop a novel adeno-associated viral vector 9 (AAV9) gene therapy for the treatment of neurofibromatosis type 2 (NF2). The therapy aims to express a healthy copy of the NF2 gene and rescue tumor characteristics in NF2...
- The University of Texas MD Anderson Cancer Center received a $1,431,215 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop T-cell products for the treatment of NF1-associated malignant peripheral nerve sheath tumors (MPNST). The project aims to discover new antigens and leverage epigenome targeting to engineer improved T-cell therapies for this rare and aggressive cancer. The award commenced on October 1, 2025, with a...
- This Project Grant award of $635,173 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to characterize the immune cell recruitment and immunosuppression mechanisms driven by the CKLF1 chemokine in MYCN-driven neuroblastoma. The award will leverage the zebrafish neuroblastoma model, patient sample analyses, in vitro co-culture systems, and mouse models to...
- This Project Grant award from the Department of the Army Medical Command totals $894,263 to The Washington University for the period of September 1, 2022 through August 31, 2025. The award supports research under the Military Medical Research and Development program (CFDA 12.420) to further understanding of the pathogenesis and prognostication of malignant peripheral nerve sheath tumors (MPNSTs) associated with Neurofibromatosis type 1 (NF1). Under the award, The Washington University will...
- The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a $1,151,209 Project Grant to The Leland Stanford Junior University (Stanford University) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will support research to investigate a novel molecular driver of schwannoma nerve sheath tumors. The project aims to study recurrent in-frame insertions or deletions in the SOX10 gene, which encodes a...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $190,485 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Trustees of Indiana University (Indiana University Indianapolis) on February 4, 2025. The grant supports research to investigate the molecular mechanisms underlying differentiation failure in neuroepithelial stem cells with NF2 gene mutations, with the goal of identifying novel therapeutic...
- The University of Texas Southwestern Medical Center will target fibrosis in neurofibromas to reduce tumor mass and enhance response to MEK inhibitors under a $860,773 project grant from the Department of the Army Medical Command. Funded through the Military Medical Research and Development program, this three-year award will support the awardee's efforts to transform Service Member healthcare and investigate medical solutions for the battlefield by developing innovative approaches for treating...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), provides $877,001 to The Washington University to conduct research aimed at "Modeling Neurofibromatosis-1 Disease Heterogeneity to Optimize Risk Assessment and Treatment." The research seeks to define the genomic, cellular, and molecular factors underlying the extreme clinical...
EVALUATING THE ROLE OF T CELLS IN NF1-PERIPHERAL NERVE SHEATH TUMOR (PNST) PROGRESSION - PROJECT SUMMARY/ABSTRACT NEUROFIBROMATOSIS TYPE 1 (NF1) IS A CANCER PREDISPOSITION SYNDROME CAUSED BY A MUTATION IN THE NF1 TUMOR SUPPRESSOR GENE THAT OCCURS IN 1:3000 LIVE BIRTHS. LOSS OF NEUROFIBROMIN, A GTPASE ACTIVATING PROTEIN FOR P21 RAS, CAUSES HYPERACTIVATION OF THE RAS PATHWAY THAT LEADS TO THE FORMATION OF PLEXIFORM NEUROFIBROMAS (PNF) IN UP TO 50% OF INDIVIDUALS WITH NF1. IN THE MAJORITY OF NF1 PATIENTS, PNF GROW SLOWLY, TYPICALLY REACHING STABILITY IN ADULTHOOD. HOWEVER, A SUBPOPULATION OF NF1 PATIENTS EXPERIENCE PROGRESSION TO ATYPICAL NEUROFIBROMATOUS NEOPLASM OF UNCERTAIN BIOLOGIC POTENTIAL (ANNUBP) AND TRANSFORM TO MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST). MPNSTS ARE THE LEADING CAUSE OF PREMATURE DEATH IN NF1 PATIENTS WITH A 5-YEAR SURVIVAL RATE OF 20- 50%. THEREFORE, UNDERSTANDING THE MOLECULAR AND CELLULAR INTERACTIONS THAT MEDIATE PROGRESSION ALONG THE PERIPHERAL NERVE SHEATH TUMOR (PNST) CONTINUUM IS CRITICAL TO IMPROVING NF1 PATIENT SURVIVAL. THE GENETIC EVENTS GOVERNING NEUROFIBROMA PROGRESSION AND MALIGNANT TRANSFORMATION HAVE BEEN EXTENSIVELY STUDIED AND SEVERAL KEY DRIVER EVENTS HAVE BEEN IMPLICATED. HOWEVER, PRECLINICAL AND NATURAL HISTORY STUDIES SUGGEST THAT THESE GENETIC CHANGES MAY NOT FULLY ACCOUNT FOR THE CLINICAL HETEROGENEITY OF PNF AND ANNUBP PRECURSOR LESIONS AND THEIR EVOLUTION TO MPNST. THEREFORE, I POSTULATE THAT ADDITIONAL FACTORS EITHER INTRINSIC TO NEOPLASTIC SCHWANN CELL PROGENITORS OR WITHIN THE TUMOR MICROENVIRONMENT PLAY A CRITICAL ROLE IN MODULATING THE GROWTH AND MALIGNANT POTENTIAL OF NEUROFIBROMA. MY RECENT WORK DEFINING THE SPATIAL GENE EXPRESSION PROFILE OF HUMAN NF1-ASSOCIATED TUMORS IDENTIFIED ALTERATIONS IN SIGNATURES OF IMMUNE SURVEILLANCE, INCLUDING T CELL ACTIVATION AND CYTOTOXICITY, ACROSS THE PNST CONTINUUM. ANTI-TUMOR T CELL RESPONSE SIGNATURES WERE UPREGULATED IN ANNUBP, WHEREAS PRECURSOR LESIONS THAT PROGRESSED TO MPNST WERE CHARACTERIZED BY SIGNATURES OF T CELL EXHAUSTION. FURTHERMORE, IMMUNOFLUORESCENCE STAINING SHOWED THAT HUMAN ANNUBPS WERE CHARACTERIZED BY INCREASED INFILTRATION OF CD4+FOXP3- AND CD8+FOXP3- T CELLS, WHILE FOXP3+ T CELLS (T REGULATORY CELLS) PREDOMINATED IN MPNST. WHILE THE DENSITY AND FUNCTIONAL STATES OF T CELLS INFILTRATING THE TUMOR MICROENVIRONMENT ARE IMPORTANT PREDICTORS OF THERAPEUTIC RESPONSE AND PROGNOSIS IN MANY HUMAN CANCERS, THE FUNCTIONAL ROLE OF DISTINCT T CELL SUBSETS IN GOVERNING NEUROFIBROMA PROGRESSION TO MPNST REMAINS UNDEFINED. THE OBJECTIVE OF THIS WORK IS TO DEFINE THE T CELL SUBSETS PRESENT AT VARIOUS STAGES OF THE PNST CONTINUUM AND INVESTIGATE THEIR FUNCTIONAL ROLE IN TUMOR PROGRESSION. I HYPOTHESIZE THAT EFFECTOR CD4 AND/OR CYTOTOXIC CD8+ T CELLS ARE CRITICAL IN PREVENTING MALIGNANT TRANSFORMATION OF PNF AND ANNUBP PRECURSORS. ULTIMATELY, THESE STUDIES WILL ADVANCE OUR UNDERSTANDING OF THE FUNCTIONAL ROLE OF T CELL SUBSETS ACROSS THE PNST CONTINUUM AND INFORM FUTURE DIAGNOSTIC AND THERAPEUTIC STRATEGIES FOR PATIENTS WITH NF1.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $41.9k | 7/21/25 | ||
| Not listed | $0 | 7/21/25 | ||
| Not listed | $41.9k | 7/21/25 |